Van ECK Associates Corp Purchases 303,395 Shares of Zoetis Inc. $ZTS

Van ECK Associates Corp boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,252,140 shares of the company’s stock after buying an additional 303,395 shares during the period. Van ECK Associates Corp owned about 1.03% of Zoetis worth $305,559,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Prosperity Bancshares Inc bought a new stake in Zoetis in the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis during the first quarter valued at approximately $28,000. Elyxium Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $32,000. Root Financial Partners LLC raised its holdings in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC raised its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus lowered their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. TD Cowen cut their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday. UBS Group reduced their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Stock Up 3.2%

Shares of NYSE:ZTS opened at $77.45 on Friday. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $156.49. The company’s 50-day moving average price is $75.57 and its two-hundred day moving average price is $95.62. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a market cap of $32.00 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.75 and a beta of 0.74.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm posted $1.76 earnings per share. The company’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.